Abstract:Carbapenemase-producing Enterobacterales have become a severe public health concern because of their rapidly transmissible resistance elements and limited treatment options. The most effective antimicrobial combinations against carbapenemase-producing Enterobacterales are currently unclear. Here, we aimed to assess the therapeutic effects of seven antimicrobial combinations (colistin-meropenem, colistin-tigecycline, colistin-rifampicin, colistin-erythromycin, meropenem-tigecycline, meropenem-rifampicin, and meropenem-tigecycline-colistin) against twenty-four carbapenem-producing Enterobacterales (producing bla KPC, bla NDM, coexisting bla NDM and bla IMP, and coexisting mcr-1/8/9 and bla NDM genes) and one carbapenem-susceptible Enterobacterales using the checkerboard assay, time-kill curves, and scanning electron microscopy. None of the combinations were antagonistic. The combination of colistin-rifampicin showed the highest synergistic effect of 76% (19/25), followed by colistin-erythromycin at 60% (15/25), meropenem-rifampicin at 24% (6/25), colistin-meropenem at 20% (5/25), colistin-tigecycline at 20% (5/25), and meropenem-tigecycline at 4% (1/25). The triple antimicrobial combinations of meropenem-tigecycline-colistin had a synergistic effect of 100%. Most double antimicrobial combinations were ineffective on isolates with coexisting bla NDM and bla IMP genes. Meropenem with tigecycline showed no synergistic effect on isolates that produced different carbapenemase genes and were highly resistant to meropenem (92% meropenem MIC ≥ 16 mg/mL). Colistin-tigecycline showed no synergistic effect on Escherichia coli producing bla NDM - 1 and Serratia marcescens. Time-kill curves showed that antimicrobial combinations achieved an eradication effect (≥ 3 log10 decreases in colony counts) within 24 h without regrowth, based on 1 × MIC of each drug. The synergistic mechanism of colistin-rifampicin may involve the colistin-mediated disruption of bacterial membranes, leading to severe alterations in their permeability, then causes more rifampicin to enter the cell and induces cell death. In conclusion, the antimicrobial combinations evaluated in this study may facilitate the successful treatment of patients infected with carbapenemase-producing pathogens.

Impact of porin deficiency on the synergistic potential of colistin in combination with β-lactam/β-lactamase inhibitors against ESBL- and carbapenemase-producing Klebsiella pneumoniae

Reduced carbapenem susceptibility in Klebsiella pneumoniae clinical isolates is due to combination of β-lactamases and the loss of OmpK36 porin

Reduced Susceptibility to Carbapenems in Klebsiella Pneumoniae Clinical Isolates Associated with Plasmid-Mediated Beta-Lactamase Production and OmpK36 Porin Deficiency.

Combination of IMP-4 metallo-β-lactamase production and porin deficiency causes carbapenem resistance in a Klebsiella oxytoca clinical isolate

The presence of high-level carbapenem resistance in Klebsiella pneumoniae is due to the combination of IMP-4 metallo-β-lactamase and porin OmpK36 deficiency

Metabolic Analyses Revealed Time-Dependent Synergistic Killing by Colistin and Aztreonam Combination Against Multidrug-Resistant Acinetobacter Baumannii

In Vivo Emergence Of Colistin Resistance In Carbapenem-Resistant Klebsiella Pneumoniae Mediated By Premature Termination Of The Mgrb Gene Regulator

Paradoxical effect of Klebsiella pneumoniae OmpK36 porin deficiency

Characterization of Porin Expression in Klebsiella Pneumoniae Carbapenemase (Kpc)-Producing K. Pneumoniae Identifies Isolates Most Susceptible to the Combination of Colistin and Carbapenems.

Comparative Metabolomics Reveals Key Pathways Associated With the Synergistic Killing of Colistin and Sulbactam Combination Against Multidrug-Resistant Acinetobacter baumannii .

Efficacy of synergistic antibiotic combinations against KPC-2 carbapenemase producing Klebsiella pneumoniae strains

Mutations of the Ompk36 Porin Gene and Promoter Impact Responses of Sequence Type 258, KPC-2-Producing Klebsiella Pneumoniae Strains to Doripenem and Doripenem-Colistin

Doripenem MICs and Ompk36 Porin Genotypes of Sequence Type 258, KPC-producing Klebsiella Pneumoniae May Predict Responses to Carbapenem-Colistin Combination Therapy among Patients with Bacteremia.

High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae.

Contribution Of Beta-Lactamases And Porin Proteins Ompk35 And Ompk36 To Carbapenem Resistance In Clinical Isolates Of Kpc-2-Producing Klebsiella Pneumoniae

In Vitro Synergistic Effect of Colistin with Fosfomycin Against Carbapenem-Resistant Klebsiella pneumoniae

Insight into Antibiotic Synergy Combinations for Eliminating Colistin Heteroresistant Klebsiella pneumoniae

In Vitro Synergistic Activity of Antimicrobial Combinations Against Blakpc and Blandm-Producing Enterobacterales with Blaimp or Mcr Genes

Doripenem, Gentamicin, and Colistin, Alone and in Combinations, Against Gentamicin-Susceptible, Kpc-Producing Klebsiella Pneumoniae Strains with Various Ompk36 Genotypes

Loss and gain of ceftazidime-avibactam susceptibility in a non-carbapenemase-producing K1-ST23 hypervirulent Klebsiella pneumoniae

The contribution of porins to enterobacterial drug resistance